Additionally, there is potential for functional interaction between incretin receptors and other GPCRs, including the SCFA-activated FFARs, to occur in the islets of Langerhans (as previously discussed), but also in the gut and the hypothalamus, all of which could influence incretin therapy responses
On the other hand, its pretty clear that once patients stop taking these GLP-1 drugs, the likelihood is that theyre going to regain weight as their metabolism normalizes and they start to consume more calories
Thousands and thousands of known compounds were individually added to these cells using robotics and whether they had any influence on the receptors was detected
Gina Vaynshteyn, Associate Vice President, Commerce at SheMedia, shares her experience below
Use a food and symptom journal to identify patterns
Altered Food Preferences: Some individuals report changes in taste perception, particularly a reduced preference for fatty and highly processed foods, suggesting GLP-1 medications reshape dietary behavior beyond just appetite suppression
